ArticleEuropean journal of medical research2026
PSMC4 promotes low-grade glioma progression and predicts poor prognosis.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-grade gliomas (LGG) are aggressive brain tumors with high rates of recurrence and poor prognosis. PSMC4, a proteasome subunit, plays a role in various cancers, but its function in LGG remains poorly understood. This study explores PSMC4's impact on LGG progression.
methodsPSMC4 expression in LGG patients was analyzed using data from TCGA, CGGA, and GEO. Kaplan-Meier and Cox regression models assessed survival outcomes. Gene Set Enrichment Analysis (GSEA) identified key pathways affected by PSMC4. Immune infiltration was evaluated using the TIMER database. In vitro, SHG44 cells were transfected with shRNA targeting PSMC4, and assays for cell proliferation, migration, clonogenicity, and invasion were performed. In vivo xenograft assays were also conducted.
resultsHigh PSMC4 expression was linked to higher tumor grade and poor prognosis in LGG patients. Kaplan-Meier analysis revealed shorter overall survival for patients with high PSMC4 expression. ROC curve analysis confirmed the diagnostic value of PSMC4 for predicting poor prognosis. GSEA identified pathways like Notch, Toll-like receptor, and VEGF signaling that may be regulated by PSMC4. In vitro, PSMC4 knockdown significantly reduced SHG44 and T98 cell proliferation, migration, and invasion, while clonogenic assays showed decreased colony formation. In vivo, PSMC4 knockdown led to smaller tumor volumes in xenograft models, confirming its role in tumor progression.
conclusionPSMC4 overexpression promotes LGG progression and may be an independent marker of poor prognosis. Targeting PSMC4 can reduce tumor growth and metastasis, providing a promising strategy for LGG treatment. Further research on its regulatory mechanisms and clinical implications is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.